Project

Exploring the therapeutic effect of Akt2/PKB- Beta –neutralising nanobodies in cancer cells

Code
3S011516
Duration
01 January 2016 → 31 December 2019
Funding
Research Foundation - Flanders (FWO)
Research disciplines
  • Natural sciences
    • Biochemistry and metabolism
    • Systems biology
  • Medical and health sciences
    • Medical biochemistry and metabolism
    • Medical biochemistry and metabolism
    • Medical biochemistry and metabolism
Keywords
Akt2/PKB- Beta Nanobody technology cancer
 
Project description

Akt2, has recently gained in importance as a therapeutic target. Although a lot of effort is being put into the development of Akt2-specific inhibitors, to date, no such inhibitor is available. Our group has obtained an Akt2-specific nanobody that triggers mitophagy in breast cancer cells. It is our objective to further characterize this nanobody and determine its therapeutic effect.